Trial Profile
A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abbott Laboratories
- 13 Aug 2012 Actual end date added as reported by ClinicalTrials.gov record.
- 13 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.